Latest news
Latigo Biotherapeutics, Clinical-Stage Developer of Selective Nav1.8 Non‑Opioid Pain Medicines for Acute and Chronic Pain, Files for Nasdaq Global Select Market IPO - TradingViewTradingView · Fri, 07 Aug 2026 20:39:00 GMTAcute pain drug Journavx helps drive Vertex growth in second quarter - Managed Healthcare ExecutiveManaged Healthcare Executive · Wed, 05 Aug 2026 15:22:30 GMTAdneuris Therapeutics - The Pharma LetterThe Pharma Letter · Wed, 05 Aug 2026 13:34:18 GMTLatigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate - Genetic Engineering and Biotechnology NewsGenetic Engineering and Biotechnology News · Thu, 30 Jul 2026 13:00:14 GMTLatigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain - Business WireBusiness Wire · Wed, 29 Jul 2026 07:00:00 GMTSodium Channel Blocker Cuts Post-Surgery Pain - MedPage TodayMedPage Today · Wed, 29 Jul 2026 07:00:00 GMT